PMID- 11342606
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20210102
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 166
IP  - 10
DP  - 2001 May 15
TI  - Human dendritic cells are activated by chimeric human papillomavirus type-16 
      virus-like particles and induce epitope-specific human T cell responses in vitro.
PG  - 5917-24
AB  - Human papillomavirus (HPV)-derived chimeric virus-like particles (VLPs) are the 
      leading candidate vaccine for the treatment or prevention of cervical cancer in 
      humans. Dendritic cells (DCs) are the most potent inducers of immune responses 
      and here we show for the first time evidence for binding of chimeric HPV-16 VLPs 
      to human peripheral blood-derived DCS: Incubation of immature human DCs with VLPs 
      for 48 h induced a significant up-regulation of the CD80 and CD83 molecules as 
      well as secretion of IL-12. Confocal microscopy analysis revealed that cell 
      surface-bound chimeric VLPs were taken up by DCS: Moreover, DCs loaded with 
      chimeric HPV-16 L1L2-E7 VLPs induced an HLA-*0201-restricted human T cell 
      response in vitro specific for E7-derived peptides. These results clearly 
      demonstrate that immature human DCs are fully activated by chimeric HPV-16 VLPs 
      and subsequently are capable of inducing endogenously processed epitope-specific 
      human T cell responses in vitro. Overall, these findings could explain the high 
      immunogenicity and efficiency of VLPs as vaccines.
FAU - Rudolf, M P
AU  - Rudolf MP
AD  - Cancer Immunology Program, Cardinal Bernardin Cancer Center, Loyola University 
      Chicago, Maywood, IL 60153, USA.
FAU - Fausch, S C
AU  - Fausch SC
FAU - Da Silva, D M
AU  - Da Silva DM
FAU - Kast, W M
AU  - Kast WM
LA  - eng
GR  - P01 CA74182/CA/NCI NIH HHS/United States
GR  - R01 CA74397/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Capsid Proteins)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (L2 protein, Human papillomavirus type 16)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Papillomavirus E7 Proteins)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (oncogene protein E7, Human papillomavirus type 16)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Antigen Presentation/genetics
MH  - Capsid/genetics/immunology/metabolism
MH  - *Capsid Proteins
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/metabolism/*virology
MH  - Epitopes, T-Lymphocyte/genetics/*immunology/metabolism
MH  - Humans
MH  - Interleukin-12/metabolism
MH  - Lipopolysaccharides/immunology
MH  - Monocytes/immunology/metabolism/virology
MH  - Oncogene Proteins, Viral/genetics/immunology/metabolism
MH  - Papillomaviridae/genetics/*immunology
MH  - Papillomavirus E7 Proteins
MH  - Peptide Mapping
MH  - Protein Binding/genetics/immunology
MH  - Recombinant Fusion Proteins/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
MH  - Tumor Necrosis Factor-alpha/immunology
MH  - Virion/genetics/*immunology
EDAT- 2001/05/09 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/05/09 10:00
PHST- 2001/05/09 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/05/09 10:00 [entrez]
AID - 10.4049/jimmunol.166.10.5917 [doi]
PST - ppublish
SO  - J Immunol. 2001 May 15;166(10):5917-24. doi: 10.4049/jimmunol.166.10.5917.